Dr. Minor is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2200 Webster St
#511
San Francisco, CA 94115
Education & Training
- Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1976 - 1978
- California Pacific Medical CenterResidency, Internal Medicine, 1974 - 1976
- University of California San Francisco School of MedicineClass of 1974
Certifications & Licensure
- CA State Medical License 1975 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Clinical Trial of Sutent to Treat Metastatic Melanoma Start of enrollment: 2007 Sep 01
- Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma Start of enrollment: 2010 Dec 01
- Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma Start of enrollment: 2013 Jul 12
- Join now to see all
Publications & Presentations
PubMed
- 148 citationsSunitinib Therapy for Melanoma Patients with KIT MutationsDavid R. Minor, Mohammed Kashani-Sabet, Maria C. Garrido, Steven J. O'Day, Omid Hamid
Clinical Cancer Research. 2012-03-01 - 2096 citationsNivolumab and ipilimumab versus ipilimumab in untreated melanomaMichael A. Postow, Jason Chesney, Anna C. Pavlick, Caroline Robert, Kenneth F. Grossmann
The New England Journal of Medicine. 2015-05-20 - 2013 citationsNivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phas...Jeffrey S. Weber, Sandra P. D'Angelo, David R. Minor, F. Stephen Hodi, Ralf Gutzmer
The Lancet. Oncology. 2015-04-01
Press Mentions
- Promising New Drug Could Help Patients Battling Deadly and Difficult to Treat Form of MelanomaMarch 8th, 2012
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: